Mycobacterium tuberculosis Beijing Type Mutation Frequency

by Jim Werngren
Published 2013-03-01

Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis

by Mikaela Glader, Sven Hoffner, Jim Werngren
Published 2015-01-01

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015

by Mikael Mansjo, Jim Werngren, Sven Hoffner
Published 2017-01-01

New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens*

by Richard M Anthony, Alice den Hertog, Mikael Mansjö, Jim Werngren
Published 2016-01-01

Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment.

by Solomon H Mariam, Jim Werngren, Joakim Aronsson, Sven Hoffner, Dan I Andersson
Published 2011-01-01

Additional drug resistance for Mycobacterium tuberculosis during turnaround time for drug-susceptibility testing in China: A multicenter observational cohort study

by Jiahui Zhu, Ziwei Bao, Yan Xie, Jim Werngren, Yi Hu, Lina Davies Forsman, Judith Bruchfeld, Sven Hoffner
Published 2021-07-01

Reduced susceptibility of clinical strains of Mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages.

by Jonna Idh, Blanka Andersson, Maria Lerm, Johanna Raffetseder, Daniel Eklund, Hanna Woksepp, Jim Werngren, Mikael Mansjö, Tommy Sundqvist, Olle Stendahl, Thomas Schön
Published 2017-01-01

Resistance to first-line anti-TB drugs is associated with reduced nitric oxide susceptibility in Mycobacterium tuberculosis.

by Jonna Idh, Mekidim Mekonnen, Ebba Abate, Wassihun Wedajo, Jim Werngren, Kristian Ängeby, Maria Lerm, Daniel Elias, Tommy Sundqvist, Abraham Aseffa, Olle Stendahl, Thomas Schön
Published 2012-01-01